TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation

NYSE:TAK • US8740602052

Current stock price

16.62 USD
-0.06 (-0.36%)
At close:
16.62 USD
0 (0%)
After Hours:

This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TAK Profitability Analysis

1.1 Basic Checks

  • TAK had positive earnings in the past year.
  • In the past year TAK had a positive cash flow from operations.
  • TAK had positive earnings in each of the past 5 years.
  • In the past 5 years TAK always reported a positive cash flow from operatings.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • TAK has a better Return On Assets (0.73%) than 81.15% of its industry peers.
  • TAK's Return On Equity of 1.48% is amongst the best of the industry. TAK outperforms 82.20% of its industry peers.
  • TAK's Return On Invested Capital of 2.32% is amongst the best of the industry. TAK outperforms 80.10% of its industry peers.
  • TAK had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 13.59%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • TAK's Profit Margin of 2.53% is amongst the best of the industry. TAK outperforms 81.68% of its industry peers.
  • In the last couple of years the Profit Margin of TAK has grown nicely.
  • The Operating Margin of TAK (10.76%) is better than 82.72% of its industry peers.
  • In the last couple of years the Operating Margin of TAK has grown nicely.
  • TAK has a better Gross Margin (65.33%) than 71.73% of its industry peers.
  • In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TAK Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TAK is still creating some value.
  • The number of shares outstanding for TAK has been increased compared to 1 year ago.
  • TAK has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TAK has been reduced compared to a year ago.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • Based on the Altman-Z score of 1.17, we must say that TAK is in the distress zone and has some risk of bankruptcy.
  • TAK has a Altman-Z score (1.17) which is in line with its industry peers.
  • TAK has a debt to FCF ratio of 6.48. This is a slightly negative value and a sign of low solvency as TAK would need 6.48 years to pay back of all of its debts.
  • TAK has a better Debt to FCF ratio (6.48) than 82.20% of its industry peers.
  • TAK has a Debt/Equity ratio of 0.56. This is a neutral value indicating TAK is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.56, TAK is not doing good in the industry: 68.06% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.17
ROIC/WACC1.42
WACC1.63%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • TAK has a Current Ratio of 1.19. This is a normal value and indicates that TAK is financially healthy and should not expect problems in meeting its short term obligations.
  • TAK has a worse Current ratio (1.19) than 81.68% of its industry peers.
  • TAK has a Quick Ratio of 1.19. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TAK has a Quick ratio of 0.65. This is amonst the worse of the industry: TAK underperforms 88.48% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TAK Growth Analysis

3.1 Past

  • TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.17%.
  • TAK shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.20% yearly.
  • The Revenue has decreased by -2.50% in the past year.
  • The Revenue has been growing slightly by 6.84% on average over the past years.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • Based on estimates for the next years, TAK will show a very strong growth in Earnings Per Share. The EPS will grow by 44.51% on average per year.
  • TAK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.47% yearly.
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. TAK Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 72.26, the valuation of TAK can be described as expensive.
  • TAK's Price/Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 78.53% of the companies in the same industry.
  • TAK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.51.
  • A Price/Forward Earnings ratio of 28.97 indicates a quite expensive valuation of TAK.
  • 74.35% of the companies in the same industry are more expensive than TAK, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.41, TAK is valued a bit more expensive.
Industry RankSector Rank
PE 72.26
Fwd PE 28.97
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 89.01% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, TAK is valued cheaper than 90.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.98
EV/EBITDA 9.94
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • TAK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of TAK may justify a higher PE ratio.
  • A more expensive valuation may be justified as TAK's earnings are expected to grow with 44.51% in the coming years.
PEG (NY)0.94
PEG (5Y)3.76
EPS Next 2Y62.14%
EPS Next 3Y44.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. TAK Dividend Analysis

5.1 Amount

  • TAK has a Yearly Dividend Yield of 3.82%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.73, TAK pays a better dividend. On top of this TAK pays more dividend than 95.81% of the companies listed in the same industry.
  • TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 3.82%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has paid a dividend for at least 10 years, which is a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years3
Div Non Decr Years4
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • 277.04% of the earnings are spent on dividend by TAK. This is not a sustainable payout ratio.
  • TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP277.04%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAK Fundamentals: All Metrics, Ratios and Statistics

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (5/1/2026, 8:04:00 PM)

After market: 16.62 0 (0%)

16.62

-0.06 (-0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners48.8%
Inst Owner Change0.02%
Ins Owners0%
Ins Owner Change22.71%
Market Cap52.51B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target20.1 (20.94%)
Short Float %0.15%
Short Ratio1.68
Dividend
Industry RankSector Rank
Dividend Yield 3.82%
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years3
Div Non Decr Years4
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)10.6%
PT rev (3m)21.71%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-17.21%
EPS NY rev (1m)1.43%
EPS NY rev (3m)1.69%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)-0.22%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE 72.26
Fwd PE 28.97
P/S 1.84
P/FCF 10.98
P/OCF 6.91
P/B 1.08
P/tB N/A
EV/EBITDA 9.94
EPS(TTM)0.23
EY1.38%
EPS(NY)0.57
Fwd EY3.45%
FCF(TTM)1.51
FCFY9.11%
OCF(TTM)2.4
OCFY14.46%
SpS9.03
BVpS15.45
TBVpS-3.29
PEG (NY)0.94
PEG (5Y)3.76
Graham Number8.94238 (-46.2%)
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.17
F-Score5
WACC1.63%
ROIC/WACC1.42
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y77.07%
EPS Next 2Y62.14%
EPS Next 3Y44.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.08%
Revenue Next 2Y0.06%
Revenue Next 3Y0.47%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year442.96%
EBIT Next 3Y77.92%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK Fundamental Analysis FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


How profitable is TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.


What is the earnings growth outlook for TAKEDA PHARMACEUTIC-SP ADR?

The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 77.07% in the next year.


Is the dividend of TAKEDA PHARMACEUTIC-SP ADR sustainable?

The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 6 / 10 and the dividend payout ratio is 277.04%.